FINWIRES · TerminalLIVE
FINWIRES

Palo Alto Networks Seen Advancing Identity Security Platform Strategy, Oppenheimer Says

By

Palo Alto Networks (PANW) is strengthening its platform strategy through the CyberArk rebrand to Idira and its integration across Strata, Cortex and Prisma, Oppenheimer said in a Friday note.

The announcement marks Palo Alto Networks' first public integration of CyberArk's technology and product roadmap into its broader security platform, the firm said.

Oppenheimer said its customer survey showed no signs of churn tied to the CyberArk acquisition. Of 22 customers surveyed, 18% expect to increase spending by more than 20% over the next 12 months, 59% expect to increase spending by 5% to 20%, and none expect cuts.

Palo Alto is also positioning agentic identity security as a key growth vector, including a Secure AI Agents solution.

Oppenheimer reiterated its outperform rating on Palo Alto and raised its price target to $275 from $245.

Price: $237.31, Change: $-0.90, Percent Change: -0.38%

Related Articles

Australia

Update: Market Chatter: Microsoft Explores AI Startup Deals as It Broadens Strategy Beyond OpenAI

(Updates with Microsoft's response in the fifth paragraph.)Microsoft (MSFT) is evaluating potential acquisitions of artificial intelligence startups as the company positions itself for a future less dependent on OpenAI, Reuters reported Wednesday, citing unnamed people familiar with the matter.Among the opportunities considered was code-generation startup Cursor, though Microsoft stepped back over concerns about regulatory scrutiny because of its ownership of GitHub Copilot, the report said.Microsoft is also in talks with Inception, a startup focused on an alternative approach to large language models, according to the report.Microsoft's venture arm, M12, participated in Inception's $50 million seed funding round in late 2025. The discussions remain ongoing and may not lead to a transaction, the report said.Microsoft declined to comment when reached by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $421.80, Change: $+12.37, Percent Change: +3.02%

$MSFT
Australia

Globant Moves Closer to Becoming an AI-Native Tech Services Firm, Wedbush Says

Globant (GLOB) is still in the early stages of its turnaround as it continues to shift focus to AI-native services, with growth anticipated to return in Q2 and accelerate in H2, Wedbush said in a Friday note.The company's Q1 total revenue beat expectations as more clients adopt its AI studios offering, with AI model independence and token sovereignty enabling flexibility for their internal use cases, Wedbush analysts said.Meanwhile, Globant's AI Pods generated $32.8 million in revenue, an increase sequentially from $20.4 million, with 40% of its top 20 customers incorporating the offering, up from 30% in the prior quarter, according to the note.The offering also expanded its sales pipeline to $352 million from $283 million in the previous quarter, positioning the company closer to becoming an AI-native tech services firm, the analysts said.Globant needs to navigate an uncertain and complex macro environment that has made clients hesitant to commit large investments, the note said.Wedbush maintained the company's stock rating at outperform and lowered the price target to $54 from $61.Price: $38.89, Change: $+4.81, Percent Change: +14.11%

$GLOB
Australia

Solventum Seen Positioned for Meaningful Re-Rating Over Next 12 to 18 Months, Wedbush Says

Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating over the next 12 to 18 months, Wedbush Securities said in a Friday research note.The brokerage said its investment thesis on Solventum centers on the divestiture or spin-off of its non-core Dental Solutions and Health Info Systems segments, adding that these businesses are "strategically misaligned" with the core Medical Surgical segment.With activist investor Trian escalating its campaign for portfolio simplification, the company's "Transform for the Future" program targets EBIT margins between 23% and 25% by fiscal 2028 and includes the $4 billion Purification & Filtration divestiture. Wedbush said Solventum is seeing a convergence of catalysts that could unlock shareholder value.The investment firm added that Solventum's stock offers an attractive entry point at current levels for investors seeking exposure to a differentiated medical technology portfolio with identifiable near-term catalysts, activist accountability, and a clear path to pure-play re-rating.Wedbush initiated coverage with an outperform rating and a $94 price target.Price: $75.43, Change: $+1.01, Percent Change: +1.36%

$SOLV